Results 31 to 40 of about 1,923,290 (310)

Alpha-fetoprotein detection of hepatocellular carcinoma leads to a standardized analysis of dynamic AFP to improve screening based detection [PDF]

, 2016
Detection of hepatocellular carcinoma (HCC) through screening can improve outcomes. However, HCC surveillance remains costly, cumbersome and suboptimal. We tested whether and how serum Alpha-Fetoprotein (AFP) should be used in HCC surveillance.
Ahn, Sang Hoon, Bird, Sheila M., Bird, Thomas G., Blunsum, Andrew, Cusack, Pearce, Dimitropoulou, Polyxeni, Hayes, Peter C., Hey, Shiying, Jenks, Sara J., Kelly, Sarah, Sturgeon, Catharine, Turner, Rebecca M.   +11 more
core   +4 more sources

ZNF561 antisense RNA 1 contributes to angiogenesis in hepatocellular carcinoma through upregulation of platelet-derived growth Factor-D

Chinese Journal of Physiology, 2022
Hepatocellular carcinoma is a common malignant tumor with high recurrence rate. Long non-coding RNA (lncRNA) ZNF561 antisense RNA 1 (ZNF561-AS1) functions as an oncogenic lncRNA to promote the tumorigenesis of colorectal cancer. The role of ZNF561-AS1 in
Jihu Zheng, Zijian Guo, Zhanchao Wen, Huikang Chen   +3 more
doaj   +1 more source

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Nature Cancer, 2022
Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. The poor outcome associated with HCC is dramatically changing due to the advent of effective systemic therapies.
J. Llovet, R. Pinyol, R. Kelley, A. El-Khoueiry, H. Reeves, X. Wang, G. Gores, A. Villanueva   +7 more
semanticscholar   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

Management of hepatocellular carcinoma: An update

Hepatology, 2011
Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
J. Bruix, M. Sherman
semanticscholar   +1 more source

Emerging Therapies for Hepatocellular Carcinoma (HCC)

Cancers, 2022
Simple Summary Primary liver cancer, also known as Hepatocellular carcinoma (HCC), is considered to be a major global health challenge. Due to delays in diagnosis at early asymptomatic stages, HCC reaches a severe aggressive stage, thereby having a ...
Eesha Chakraborty, D. Sarkar
semanticscholar   +1 more source

The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment [PDF]

, 2014
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third leading cause of cancer deaths. microRNAs (miRNAs) are evolutionary conserved small non-coding RNA that negatively regulate gene expression and protein translation ...
Bianconi Maristella, Cascinu Stefano, D'Anzeo Marco, Del Prete Michela, Faloppi Luca, Giampieri Riccardo, SCARTOZZI, MARIO, Silvestris Nicola   +7 more
core   +1 more source

CEUS LI-RADS: a pictorial review [PDF]

, 2020
Contrast-enhanced ultrasound (CEUS) greatly improved the diagnostic accuracy of US in the detection and characterization of focal liver lesions (FLLs), and it is suggested and often included in many international guidelines as an important diagnostic ...
Bartolotta, Tommaso Vincenzo, Gagliardo, Cesare, Taibbi, Adele, Terranova, Maria Chiara   +3 more
core   +1 more source

Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. [PDF]

, 2018
Fibrolamellar carcinoma has a distinctive morphology and immunophenotype, including cytokeratin 7 and CD68 co-expression. Despite the distinct findings, accurate diagnosis of fibrolamellar carcinoma continues to be a challenge.
Alves, Venancio Af, Cruise, Michael W, Ferrell, Linda, Gill, Ryan M, Graham, Rondell P, Greipp, Patricia T, Jain, Dhanpat, Jin, Long, Kakar, Sanjay, Kerr, Sarah E, Lam-Himlin, Dora, Longerich, Thomas, Nart, Deniz, Roberts, Lewis R, Roessler, Stephanie, Rustin, Jeanette G, Salaria, Safia N, Schirmacher, Peter, Solomon, David A, Sukov, William R, Terracciano, Luigi, Torbenson, Michael S, Wang, Xiaoke, Waterhouse, Emily, Yeh, Matthew M, Yilmaz, Funda, Zaid, Nida, Zreik, Riyam T   +27 more
core   +1 more source

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

Liver Cancer, 2021
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH ...
M. Kudo, Y. Kawamura, K. Hasegawa, R. Tateishi, K. Kariyama, S. Shiina, H. Toyoda, Y. Imai, A. Hiraoka, M. Ikeda, N. Izumi, M. Moriguchi, S. Ogasawara, Y. Minami, K. Ueshima, T. Murakami, S. Miyayama, O. Nakashima, H. Yano, M. Sakamoto, E. Hatano, M. Shimada, N. Kokudo, S. Mochida, T. Takehara   +24 more
semanticscholar   +1 more source